The American College of Cardiology and Heart Rhythm Society, in collaboration with the Bristol Myers Squibb-Pfizer Alliance, are launching an innovative project to improve management of atrial fibrillation in underserved communities.
In response to the COVID-19 pandemic, the Heart Rhythm Society (HRS) led a global cross-sectional survey of more than 1,100 electrophysiologists (EPs) to better understand the prevalence of cardiac arrhythmias and treatment strategies in hospitalized COVID-19 patients.
A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or paroxysmal atrial fibrillation (AF) and showcases a novel approach to performing point-by-point ablation to provide safe and effective patient outcomes.
A new clinical study found that patients with atrial fibrillation (AF) experienced a high incidence of clinically silent brain infarcts, despite taking oral anticoagulants for stroke prevention. Silent brain infarcts were significantly associated with cognitive decline.
A new clinical trial is the first to compare the safety and efficacy of subcutaneous implantable cardioverter defibrillators (S-ICDs) to transvenous implantable cardioverter-defibrillators (TV-ICD).
New clinical trial revealed the first-in-human results for paroxysmal or persistent atrial fibrillation (AF) treated with a novel energy source – pulsed field ablation (PFA).
Results of a clinical trial released today show stark disparities in the use of life-saving implantable cardiverter defibrillator (ICD) interventions based on sex and race, suggesting potential bias in care pathways by electrophysiologists (EPs).
A new study reveals that drinking a couple of daily cups of coffee does not lead to a greater risk of arrhythmias, potentially debunking a common myth that consuming caffeine in coffee and other drinks could lead to a faster heartbeat and the potential for a triggered arrhythmia for this patient